HC Wainwright Reaffirms Buy Rating for KalVista Pharmaceuticals (NASDAQ:KALV)

KalVista Pharmaceuticals (NASDAQ:KALV)‘s stock had its “buy” rating reaffirmed by HC Wainwright in a report issued on Friday,Benzinga reports. They currently have a $20.00 price target on the specialty pharmaceutical company’s stock. HC Wainwright’s price target would indicate a potential upside of 58.73% from the company’s previous close.

A number of other analysts have also commented on KALV. TD Cowen assumed coverage on shares of KalVista Pharmaceuticals in a research note on Tuesday, January 7th. They set a “buy” rating and a $30.00 price target for the company. Cantor Fitzgerald restated an “overweight” rating on shares of KalVista Pharmaceuticals in a research note on Monday, December 9th. Needham & Company LLC restated a “buy” rating and set a $28.00 price target on shares of KalVista Pharmaceuticals in a research note on Thursday. Bank of America initiated coverage on shares of KalVista Pharmaceuticals in a research note on Wednesday, December 18th. They issued a “buy” rating and a $22.00 target price for the company. Finally, JMP Securities initiated coverage on shares of KalVista Pharmaceuticals in a research note on Friday, January 31st. They issued an “outperform” rating and a $19.00 target price for the company. Six analysts have rated the stock with a buy rating and one has given a strong buy rating to the company’s stock. According to MarketBeat, the company currently has an average rating of “Buy” and a consensus target price of $23.80.

KalVista Pharmaceuticals Trading Up 2.9 %

Shares of KALV stock opened at $12.60 on Friday. The firm has a market capitalization of $622.67 million, a PE ratio of -3.46 and a beta of 0.76. The firm has a fifty day simple moving average of $9.75 and a two-hundred day simple moving average of $10.28. KalVista Pharmaceuticals has a 12 month low of $7.30 and a 12 month high of $15.50.

Insider Transactions at KalVista Pharmaceuticals

In related news, insider Paul K. Audhya sold 3,125 shares of the business’s stock in a transaction dated Tuesday, February 18th. The shares were sold at an average price of $9.82, for a total value of $30,687.50. Following the transaction, the insider now directly owns 100,334 shares of the company’s stock, valued at approximately $985,279.88. The trade was a 3.02 % decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, CEO Benjamin L. Palleiko sold 6,669 shares of the business’s stock in a transaction dated Friday, March 7th. The stock was sold at an average price of $11.97, for a total transaction of $79,827.93. Following the completion of the transaction, the chief executive officer now directly owns 287,811 shares in the company, valued at $3,445,097.67. This trade represents a 2.26 % decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last quarter, insiders bought 236,055 shares of company stock worth $2,162,146 and sold 17,292 shares worth $184,625. Company insiders own 10.50% of the company’s stock.

Hedge Funds Weigh In On KalVista Pharmaceuticals

A number of hedge funds and other institutional investors have recently made changes to their positions in the stock. SG Americas Securities LLC lifted its holdings in KalVista Pharmaceuticals by 10.0% during the fourth quarter. SG Americas Securities LLC now owns 14,508 shares of the specialty pharmaceutical company’s stock valued at $123,000 after purchasing an additional 1,319 shares during the last quarter. HighVista Strategies LLC lifted its holdings in KalVista Pharmaceuticals by 4.5% during the third quarter. HighVista Strategies LLC now owns 33,305 shares of the specialty pharmaceutical company’s stock valued at $386,000 after purchasing an additional 1,432 shares during the last quarter. Legal & General Group Plc lifted its holdings in KalVista Pharmaceuticals by 22.5% during the fourth quarter. Legal & General Group Plc now owns 8,144 shares of the specialty pharmaceutical company’s stock valued at $69,000 after purchasing an additional 1,494 shares during the last quarter. JPMorgan Chase & Co. lifted its holdings in KalVista Pharmaceuticals by 8.0% during the third quarter. JPMorgan Chase & Co. now owns 22,610 shares of the specialty pharmaceutical company’s stock valued at $262,000 after purchasing an additional 1,670 shares during the last quarter. Finally, China Universal Asset Management Co. Ltd. lifted its holdings in KalVista Pharmaceuticals by 24.7% during the fourth quarter. China Universal Asset Management Co. Ltd. now owns 10,329 shares of the specialty pharmaceutical company’s stock valued at $87,000 after purchasing an additional 2,043 shares during the last quarter.

KalVista Pharmaceuticals Company Profile

KalVista Pharmaceuticals, Inc, a clinical stage pharmaceutical company, engages in the discovery, development, and commercialization of drug therapies inhibitors for diseases with unmet needs. The company’s product candidate is Sebetralstat, a small molecule plasma kallikrein inhibitor targeting the disease of hereditary angioedema (HAE).